Proper assessment of medical values and innovativeness of IVDs
Committee:
IVD (In Vitro Diagnostics)status:
Good progress
Published:
The medical value and innovativeness of IVDs have not been directly reflected to reimbursement point discussion. In the 2024 revision of the medical fee, a "marketability premium" was recognized as one of the innovation evaluations in IVDs. Additionally, a challenge application system was also introduced.
Recommendations
- One of the utilities of IVDs is "cost-effectiveness" (efficiency in healthcare). EBC requests the inclusion of cost-effectiveness evaluation as an assessment criterion for the usefulness and innovativeness of tests.